[Corrected 7/27/15, 1.49pm. See below.] Spun out of its namesake two years ago, vaccine maker SutroVax has reeled in a $22 million Series A round to push forward a type of vaccine that uses sophisticated chemistry to boost its... Read more »
Wisconsin startup accelerator Gener8tor has launched a free business training program to nurture young companies with ties to Badger State universities—and perhaps build a more direct pipeline of local companies for its main for-profit program.
The new initiative, dubbed gBETA, is... Read more »
Ginkgo Bioworks has raised its second round of funding this year, a $45 million Series B, which it plans to use to create new kinds of synthetically engineered organisms and build a second production facility.
The Boston-based company designs and builds... Read more »
The University of Michigan unveiled MCity this week to a throng of international media and local dignitaries on hand to check out the $6.5 million, 32-acre controlled environment specifically designed to test the potential of connected and automated vehicle technologies.
The... Read more »
Scynexis, which has straddled the drug business as both a drug developer and a services provider for other pharmaceutical companies, is now exclusively focused on developing its own drugs.
The Durham, NC, company announced Thursday that it has sold its... Read more »
Exact Sciences is significantly boosting its coffers as it continues pushing sales of its first molecular diagnostic test and goes to work developing more products.
Madison, WI-based Exact (NASDAQ: EXAS) said it expects to earn about $174 million this week... Read more »
The concept of “disruption” has become a buzzword in biotech, a term signifying the dreams of companies looking to make a big impact on the world of healthcare. Yet that type of risk-taking and innovation typifies the startup biotech, where the... Read more »
When you think of wireless power—the ability to charge a device without a power cord—most people in Boston think of WiTricity, the MIT spinout that has raised north of $45 million and has partnerships with Toyota and Intel.
But there’s... Read more »
Ra Pharmaceuticals, a Cambridge,MA-based company that signed a large collaboration deal with Merck two years ago, has received a $58.5 million Series B financing to take its first drug, a potential treatment for an ultra-rare blood disorder, called paroxysmal nocturnal hemoglobinuria,... Read more »